Abstract: Early screening with <sup>18</sup>F-FLT and <sup>18</sup>F-FMISO tracers has important clinical value for the efficient diagnosis and treatment of colorectal cancer liver metastases.
Introduction
Colorectal cancer (CRC) is a major global health concern, with liver metastasis being the primary cause of cancer-related mortality. While Positron Emission Tomography (PET) imaging is a cornerstone of oncological diagnosis, the most common tracer, $^{18}$F-FDG, primarily measures glucose metabolism. This approach often struggles to distinguish between aggressive metastatic lesions and slow-growing tumors or inflammatory tissues, as both can exhibit high glucose uptake.
Recent research has identified the oncogene MACC1 (Metastasis-associated in colon cancer 1) and its downstream effector SPON2 (Spondin 2) as critical drivers of CRC progression. This study evaluates whether alternative PET tracers targeting cell proliferation ($^{18}$F-FLT) and hypoxia ($^{18}$F-FMISO) can serve as better indicators of metastatic potential by correlating with these molecular markers.
Methodology
The researchers employed a dual-track experimental design:
- Cell Models: Two human CRC cell lines were used: LoVo (high metastatic potential) and HCT8 (low metastatic potential).
- Animal Models: Liver metastasis was established by injecting these cell lines into the spleens of nude mice.
- Multi-Tracer PET Imaging: Micro-PET scans were conducted using three tracers:
- $^{18}$F-FDG: To measure glucose metabolism.
- $^{18}$F-FLT: To measure cell proliferation via thymidine kinase-1 activity.
- $^{18}$F-FMISO: To measure tumor hypoxia.
- Molecular Validation: Post-imaging, tumor tissues were analyzed via Western blot and immunohistochemistry to quantify MACC1 and SPON2 expression, which were then correlated with PET uptake values (SUVmax).
Key Results and Discussion
The Specificity Gap of $^{18}$F-FDG
The study confirmed that while $^{18}$F-FDG is highly sensitive, it lacks the specificity required to predict tumor aggressiveness. In the mouse models, $^{18}$F-FDG uptake showed no statistically significant difference between the high-metastatic LoVo tumors and the low-metastatic HCT8 tumors ($P > 0.05$).
Superiority of $^{18}$F-FLT and $^{18}$F-FMISO
In contrast, both $^{18}$F-FLT and $^{18}$F-FMISO were able to distinguish between the two cell lines, with significantly higher uptake observed in the aggressive LoVo tumors ($P < 0.05$).
Correlation with MACC1 and SPON2
The most significant finding was the strong correlation between tracer uptake and molecular drivers. The uptake of $^{18}$F-FLT correlated strongly with both MACC1 ($r = 0.737$) and SPON2 ($r = 0.842$) expression, while $^{18}$F-FMISO uptake correlated significantly with MACC1 ($r = 0.770$). These results suggest that $^{18}$F-FLT and $^{18}$F-FMISO PET scans can act as non-invasive proxies for the genetic activity driving metastasis. Specifically, $^{18}$F-FLT provides a window into the proliferative engine fueled by the MACC1-SPON2 pathway.
Conclusion
While $^{18}$F-FDG remains a sensitive tool for detecting lesions, $^{18}$F-FLT and $^{18}$F-FMISO offer superior specificity for identifying high-risk, aggressive colorectal liver metastases. Despite limitations such as small animal sample sizes and manual ROI selection, these findings pave the way for more precise, molecularly-targeted diagnostic strategies in clinical oncology. Future work should focus on clinical translation and the development of automated imaging analysis to enhance diagnostic reliability.
Summary updated